Pulmonary deposition and clearance of aerosolized interferon.
Small particle aerosols of a hybrid DNA recombinant human alpha interferon, A/D bgl, and a related DNA recombinant leukocyte interferon, A, were generated and delivered to mice for 23.5 h a day for 4 consecutive days. The antiviral activity of these interferons in delivery reservoirs, in the aerosols generated, and in the lungs of test mice was monitored during and after aerosol administration in cytopathic effect inhibition assays, using vesicular stomatitis virus as the indicator virus. In addition, the activity of these interferons in primary mouse embryo cells against influenza A/HK/68 (H3N2) virus was determined. The results obtained indicated that the interferon particles generated in the continuous aerosol therapy system used in these studies remained biologically active and could be readily detected in both aerosol mists and lungs of test mice; levels of exogenous interferon in the lungs equalled or exceeded levels of interferons produced endogenously during experimentally induced influenza virus infection. Titers of the exogenously administered interferons decreased gradually and disappeared from the lungs between 24 and 48 h after cessation of aerosolization. Recombinant human alpha interferon A/D, but not recombinant leukocyte alpha interferon A, significantly inhibited replication of A/HK/68 virus in primary mouse embryo cells in the in vitro studies.
D000336:Aerosols; D000818:Animals; D000998:Antiviral Agents; D046508:Culture Techniques; D004355:Drug Stability; D007370:Interferon Type I / Q000008:administration & dosage / Q000378:metabolism* / Q000494:pharmacology; D008168:Lung / Q000378:metabolism*; D051379:Mice; D009975:Orthomyxoviridae / Q000276:immunology; D010316:Particle Size; D013997:Time Factors
D000336:Aerosols; D000998:Antiviral Agents; D007370:Interferon Type I